P53‑microRNA interactions regulate the response of colorectal tumor cells to oxaliplatin under normoxic and hypoxic conditions

Zhang,Jiayu; Li,Chenguang; Sun,Luanbiao; Sun,Denghua; Zhao,Tiancheng

doi:10.3892/or.2023.8656

December-2023 Volume 50 Issue 6

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

December-2023 Volume 50 Issue 6

Full Size Image

Article Open Access

P53‑microRNA interactions regulate the response of colorectal tumor cells to oxaliplatin under normoxic and hypoxic conditions

Authors:
- Jiayu Zhang
- Chenguang Li
- Luanbiao Sun
- Denghua Sun
- Tiancheng Zhao
View Affiliations / Copyright

Affiliations: Gastrointestinal Colorectal and Anal Surgery, China‑Japan Union Hospital of Jilin University, Changchun, Jilin 130033, P.R. China, Department of Breast Surgery, China‑Japan Union Hospital of Jilin University, Changchun, Jilin 130033, P.R. China, Department of Endoscopy Center, China‑Japan Union Hospital of Jilin University, Changchun, Jilin 130033, P.R. China

Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
Article Number: 219
|
Published online on: October 31, 2023

https://doi.org/10.3892/or.2023.8656
Expand metrics +

Abstract

Oxaliplatin (OXA)‑containing regimens are used as first‑line chemotherapy in colorectal cancer (CRC). However, OXA resistance remains a major challenge in CRC treatment. CRC cells that adapt to hypoxia can potentially develop OXA resistance, and the underlying molecular mechanisms still need to be further investigated. In the current study, the OXA drug sensitivity of two CRC cell lines, HCT116 (TP53^WT) and HT29 (TP53^MT), was compared under both normoxic and hypoxic conditions. It was found that under normoxic condition, HCT116 cells showed significantly higher OXA sensitivity than HT29 cells. However, both cell lines showed remarkable OXA resistance under hypoxic conditions. It was also revealed that P53 levels were increased after OXA and hypoxia treatment in HCT116 cells but not in HT29 cells. Notably, knocking down P53^WT decreased normoxic but increased hypoxic OXA sensitivity in HCT116 cells, which did not exist in HT29 cells. Molecular analysis indicated that P53^WT activated microRNA (miR)‑26a and miR‑34a in OXA treatment and activated miR‑23a in hypoxia treatment. Cell proliferation experiments indicated that a high level of miR‑23a decreased OXA sensitivity and that a high level of miR‑26a or miR‑34a increased OXA sensitivity in HCT116 cells. Additionally, it was demonstrated that miR‑26a, miR‑34a and miR‑23a affect cell apoptosis through regulation of MCL‑1, EZH2, BCL‑2, SMAD 4 and STAT3. Taken together, the present findings revealed the dual function of P53 in regulating cellular chemo‑sensitivity and highlighted the role of P53‑miR interactions in the response of CRC cells to OXA chemotherapy under normoxic and hypoxic conditions.

View Figures

View References

1	Cai J and Wang L: Looking back 2018-focused on colorectal cancer. Zhonghua Wei Chang Wai Ke Za Zhi. 22:9–16. 2019.(In Chinese). PubMed/NCBI
2	Quirke P, Durdey P, Dixon MF and Williams NS: Local recurrence of rectal adenocarcinoma due to inadequate surgical resection. Histopathological study of lateral tumour spread and surgical excision. Lancet. 2:996–999. 1986. View Article : Google Scholar : PubMed/NCBI
3	Hsu HH, Chen MC, Baskaran R, Lin YM, Day CH, Lin YJ, Tu CC, Vijaya Padma V, Kuo WW and Huang CY: Oxaliplatin resistance in colorectal cancer cells is mediated via activation of ABCG2 to alleviate ER stress induced apoptosis. J Cell Physiol. 233:5458–5467. 2018. View Article : Google Scholar : PubMed/NCBI
4	Yang C, Zhou Q, Li M, Tong X, Sun J, Qing Y, Sun L, Yang X, Hu X, Jiang J, et al: Upregulation of CYP2S1 by oxaliplatin is associated with p53 status in colorectal cancer cell lines. Sci Rep. 6:330782016. View Article : Google Scholar : PubMed/NCBI
5	Meads MB, Gatenby RA and Dalton WS: Environment-mediated drug resistance: A major contributor to minimal residual disease. Nat Rev Cancer. 9:665–674. 2009. View Article : Google Scholar : PubMed/NCBI
6	Martinez-Balibrea E, Martínez-Cardús A, Ginés A, Ruiz de Porras V, Moutinho C, Layos L, Manzano JL, Bugés C, Bystrup S, Esteller M and Abad A: Tumor-related molecular mechanisms of oxaliplatin resistance. Mol Cancer Ther. 14:1767–1776. 2015. View Article : Google Scholar : PubMed/NCBI
7	Plasencia C, Martinez-Balibrea E, Martinez-Cardús A, Quinn DI, Abad A and Neamati N: Expression analysis of genes involved in oxaliplatin response and development of oxaliplatin-resistant HT29 colon cancer cells. Int J Oncol. 29:225–235. 2006.PubMed/NCBI
8	Pedraz-Cuesta E, Christensen S, Jensen AA, Jensen NF, Bunch L, Romer MU, Brünner N, Stenvang J and Pedersen SF: The glutamate transport inhibitor DL-Threo-β-Benzyloxyaspartic acid (DL-TBOA) differentially affects SN38- and oxaliplatin-induced death of drug-resistant colorectal cancer cells. BMC Cancer. 15:4112015. View Article : Google Scholar : PubMed/NCBI
9	Liao X, Song G, Xu Z, Bu Y, Chang F, Jia F, Xiao X, Ren X, Zhang M and Jia Q: Oxaliplatin resistance is enhanced by saracatinib via upregulation Wnt-ABCG1 signaling in hepatocellular carcinoma. BMC Cancer. 20:312020. View Article : Google Scholar : PubMed/NCBI
10	Hubbi ME and Semenza GL: Regulation of cell proliferation by hypoxia-inducible factors. Am J Physiol Cell Physiol. 309:C775–C782. 2015. View Article : Google Scholar : PubMed/NCBI
11	Pugh CW and Ratcliffe PJ: Regulation of angiogenesis by hypoxia: Role of the HIF system. Nat Med. 9:677–684. 2003. View Article : Google Scholar : PubMed/NCBI
12	Gilkes DM, Semenza GL and Wirtz D: Hypoxia and the extracellular matrix: Drivers of tumour metastasis. Nat Rev Cancer. 14:430–439. 2014. View Article : Google Scholar : PubMed/NCBI
13	Tang YA, Chen YF, Bao Y, Mahara S, Yatim SMJM, Oguz G, Lee PL, Feng M, Cai Y, Tan EY, et al: Hypoxic tumor microenvironment activates GLI2 via HIF-1α and TGF-β2 to promote chemoresistance in colorectal cancer. Proc Natl Acad Sci USA. 115:E5990–E5999. 2018. View Article : Google Scholar : PubMed/NCBI
14	Roberts DL, Williams KJ, Cowen RL, Barathova M, Eustace AJ, Brittain-Dissont S, Tilby MJ, Pearson DG, Ottley CJ, Stratford IJ and Dive C: Contribution of HIF-1 and drug penetrance to oxaliplatin resistance in hypoxic colorectal cancer cells. Br J Cancer. 101:1290–1297. 2009. View Article : Google Scholar : PubMed/NCBI
15	Gariboldi MB, Taiana E, Bonzi MC, Craparotta I, Giovannardi S, Mancini M and Monti E: The BH3-mimetic obatoclax reduces HIF-1α levels and HIF-1 transcriptional activity and sensitizes hypoxic colon adenocarcinoma cells to 5-fluorouracil. Cancer Lett. 364:156–164. 2015. View Article : Google Scholar : PubMed/NCBI
16	Nijhuis A, Thompson H, Adam J, Parker A, Gammon L, Lewis A, Bundy JG, Soga T, Jalaly A, Propper D, et al: Remodelling of microRNAs in colorectal cancer by hypoxia alters metabolism profiles and 5-fluorouracil resistance. Hum Mol Genet. 26:1552–1564. 2017. View Article : Google Scholar : PubMed/NCBI
17	Xu K, Zhan Y, Yuan Z, Qiu Y, Wang H, Fan G, Wang J, Li W, Cao Y, Shen X, et al: Hypoxia induces drug resistance in colorectal cancer through the HIF-1α/miR-338-5p/IL-6 feedback loop. Mol Ther. 27:1810–1824. 2019. View Article : Google Scholar : PubMed/NCBI
18	Therachiyil L, Haroon J, Sahir F, Siveen KS, Uddin S, Kulinski M, Buddenkotte J, Steinhoff M and Krishnankutty R: Dysregulated phosphorylation of p53, autophagy and stemness attributes the mutant p53 harboring colon cancer cells impaired sensitivity to oxaliplatin. Front Oncol. 10:17442020. View Article : Google Scholar : PubMed/NCBI
19	Shang L and Wei M: Inhibition of SMYD2 sensitized cisplatin to resistant cells in NSCLC through activating p53 pathway. Front Oncol. 9:3062019. View Article : Google Scholar : PubMed/NCBI
20	Takayama T, Miyanishi K, Hayashi T, Sato Y and Niitsu Y: Colorectal cancer: Genetics of development and metastasis. J Gastroenterol. 41:185–192. 2006. View Article : Google Scholar : PubMed/NCBI
21	Huang D, Sun W, Zhou Y, Li P, Chen F, Chen H, Xia D, Xu E, Lai M, Wu Y and Zhang H: Mutations of key driver genes in colorectal cancer progression and metastasis. Cancer Metastasis Rev. 37:173–187. 2018. View Article : Google Scholar : PubMed/NCBI
22	Sui X, Kong N, Wang X, Fang Y, Hu X, Xu Y, Chen W, Wang K, Li D, Jin W, et al: JNK confers 5-fluorouracil resistance in p53-deficient and mutant p53-expressing colon cancer cells by inducing survival autophagy. Sci Rep. 4:46942014. View Article : Google Scholar : PubMed/NCBI
23	Ikediobi ON, Davies H, Bignell G, Edkins S, Stevens C, O'Meara S, Santarius T, Avis T, Barthorpe S, Brackenbury L, et al: Mutation analysis of 24 known cancer genes in the NCI-60 cell line set. Mol Cancer Ther. 5:2606–2612. 2006. View Article : Google Scholar : PubMed/NCBI
24	Park JY, Park SJ, Shim KY, Lee KJ, Kim YB, Kim YH and Kim SK: Echinomycin and a novel analogue induce apoptosis of HT-29 cells via the activation of MAP kinases pathway. Pharmacol Res. 50:201–207. 2004. View Article : Google Scholar : PubMed/NCBI
25	Kim JS, Lee C, Bonifant CL, Ressom H and Waldman T: Activation of p53-dependent growth suppression in human cells by mutations in PTEN or PIK3CA. Mol Cell Biol. 27:662–677. 2007. View Article : Google Scholar : PubMed/NCBI
26	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
27	Meng X, Sun W, Yu J, Zhou Y, Gu Y, Han J, Zhou L, Jiang X and Wang C: LINC00460-miR-149-5p/miR-150-5p-mutant p53 feedback loop promotes oxaliplatin resistance in colorectal cancer. Mol Ther Nucleic Acids. 22:1004–1015. 2020. View Article : Google Scholar : PubMed/NCBI
28	Maqbool R, Lone SN and Ul Hussain M: Post-transcriptional regulation of the tumor suppressor p53 by a novel miR-27a, with implications during hypoxia and tumorigenesis. Biochem J. 473:3597–3610. 2016. View Article : Google Scholar : PubMed/NCBI
29	Li H, Rokavec M, Jiang L, Horst D and Hermeking H: Antagonistic effects of p53 and HIF1A on microRNA-34a regulation of PPP1R11 and STAT3 and hypoxia-induced epithelial to mesenchymal transition in colorectal cancer cells. Gastroenterology. 153:505–520. 2017. View Article : Google Scholar : PubMed/NCBI
30	Kiyonari S, Iimori M, Matsuoka K, Watanabe S, Morikawa-Ichinose T, Miura D, Niimi S, Saeki H, Tokunaga E, Oki E, et al: The 1,2-diaminocyclohexane carrier ligand in oxaliplatin induces p53-dependent transcriptional repression of factors involved in thymidylate biosynthesis. Mol Cancer Ther. 14:2332–2342. 2015. View Article : Google Scholar : PubMed/NCBI
31	Moradi Marjaneh R, Khazaei M, Ferns GA, Avan A and Aghaee-Bakhtiari SH: MicroRNAs as potential therapeutic targets to predict responses to oxaliplatin in colorectal cancer: From basic evidence to therapeutic implication. IUBMB Life. 71:1428–1441. 2019. View Article : Google Scholar : PubMed/NCBI
32	Islam SU, Ahmed MB, Sonn JK, Jin EJ and Lee YS: PRP4 induces epithelial-mesenchymal transition and drug resistance in colon cancer cells via activation of p53. Int J Mol Sci. 23:30922022. View Article : Google Scholar : PubMed/NCBI
33	Du Y, Wei N, Ma R, Jiang S and Song D: A miR-210-3p regulon that controls the Warburg effect by modulating HIF-1α and p53 activity in triple-negative breast cancer. Cell Death Dis. 11:7312020. View Article : Google Scholar : PubMed/NCBI
34	Nersisyan S, Galatenko A, Chekova M and Tonevitsky A: Hypoxia-induced miR-148a downregulation contributes to poor survival in colorectal cancer. Front Genet. 12:6624682021. View Article : Google Scholar : PubMed/NCBI
35	Ullmann P, Qureshi-Baig K, Rodriguez F, Ginolhac A, Nonnenmacher Y, Ternes D, Weiler J, Gäbler K, Bahlawane C, Hiller K, et al: Hypoxia-responsive miR-210 promotes self-renewal capacity of colon tumor-initiating cells by repressing ISCU and by inducing lactate production. Oncotarget. 7:65454–65470. 2016. View Article : Google Scholar : PubMed/NCBI
36	Evert J, Pathak S, Sun XF and Zhang H: A study on effect of oxaliplatin in MicroRNA expression in human colon cancer. J Cancer. 9:2046–2053. 2018. View Article : Google Scholar : PubMed/NCBI
37	Yamakuchi M, Lotterman CD, Bao C, Hruban RH, Karim B, Mendell JT, Huso D and Lowenstein CJ: P53-induced microRNA-107 inhibits HIF-1 and tumor angiogenesis. Proc Natl Acad Sci USA. 107:6334–6339. 2010. View Article : Google Scholar : PubMed/NCBI
38	Wang X, Yu M, Zhao K, He M, Ge W, Sun Y, Wang Y, Sun H and Hu Y: Upregulation of MiR-205 under hypoxia promotes epithelial-mesenchymal transition by targeting ASPP2. Cell Death Dis. 7:e25172016. View Article : Google Scholar : PubMed/NCBI
39	Jin F, Yang R, Wei Y, Wang D, Zhu Y, Wang X, Lu Y, Wang Y, Zen K and Li L: HIF-1α-induced miR-23a~27a~24 cluster promotes colorectal cancer progression via reprogramming metabolism. Cancer Lett. 440–441. 211–222. 2019.
40	Qian X, Yu J, Yin Y, He J, Wang L, Li Q, Zhang LQ, Li CY, Shi ZM, Xu Q, et al: MicroRNA-143 inhibits tumor growth and angiogenesis and sensitizes chemosensitivity to oxaliplatin in colorectal cancers. Cell Cycle. 12:1385–1394. 2013. View Article : Google Scholar : PubMed/NCBI
41	He C, Wang L, Zhang J and Xu H: Hypoxia-inducible microRNA-224 promotes the cell growth, migration and invasion by directly targeting RASSF8 in gastric cancer. Mol Cancer. 16:352017. View Article : Google Scholar : PubMed/NCBI
42	Chen HY, Lin YM, Chung HC, Lang YD, Lin CJ, Huang J, Wang WC, Lin FM, Chen Z, Huang HD, et al: miR-103/107 promote metastasis of colorectal cancer by targeting the metastasis suppressors DAPK and KLF4. Cancer Res. 72:3631–3641. 2012. View Article : Google Scholar : PubMed/NCBI
43	Sun Z, Zhang Q, Yuan W, Li X, Chen C, Guo Y, Shao B, Dang Q, Zhou Q, Wang Q, et al: MiR-103a-3p promotes tumour glycolysis in colorectal cancer via hippo/YAP1/HIF1A axis. J Exp Clin Cancer Res. 39:2502020. View Article : Google Scholar : PubMed/NCBI
44	Tang Y, Weng X, Liu C, Li X and Chen C: Hypoxia enhances activity and malignant behaviors of colorectal cancer cells through the STAT3/MicroRNA-19a/PTEN/PI3K/AKT axis. Anal Cell Pathol (Amst). 2021:41324882021.PubMed/NCBI
45	Kim CW, Oh ET, Kim JM, Park JS, Lee DH, Lee JS, Kim KK and Park HJ: Hypoxia-induced microRNA-590-5p promotes colorectal cancer progression by modulating matrix metalloproteinase activity. Cancer Lett. 416:31–41. 2018. View Article : Google Scholar : PubMed/NCBI
46	Xu K, Chen G, Qiu Y, Yuan Z, Li H, Yuan X, Sun J, Xu J, Liang X and Yin P: miR-503-5p confers drug resistance by targeting PUMA in colorectal carcinoma. Oncotarget. 8:21719–21732. 2017. View Article : Google Scholar : PubMed/NCBI
47	Saieva L, Barreca MM, Zichittella C, Prado MG, Tripodi M, Alessandro R and Conigliaro A: Hypoxia-induced miR-675-5p supports β-catenin nuclear localization by regulating GSK3-β activity in colorectal cancer cell lines. Int J Mol Sci. 21:38322020. View Article : Google Scholar : PubMed/NCBI
48	Costa V, Lo Dico A, Rizzo A, Rajata F, Tripodi M, Alessandro R and Conigliaro A: MiR-675-5p supports hypoxia induced epithelial to mesenchymal transition in colon cancer cells. Oncotarget. 8:24292–24302. 2017. View Article : Google Scholar : PubMed/NCBI
49	Poel D, Boyd LNC, Beekhof R, Schelfhorst T, Pham TV, Piersma SR, Knol JC, Jimenez CR, Verheul HMW and Buffart TE: Proteomic analysis of miR-195 and miR-497 replacement reveals potential candidates that increase sensitivity to oxaliplatin in MSI/P53wt colorectal cancer cells. Cells. 8:11112019. View Article : Google Scholar : PubMed/NCBI
50	Dong Y, Zhao J, Wu CW, Zhang L, Liu X, Kang W, Leung WW, Zhang N, Chan FK, Sung JJ, et al: Tumor suppressor functions of miR-133a in colorectal cancer. Mol Cancer Res. 11:1051–1060. 2013. View Article : Google Scholar : PubMed/NCBI
51	Moriondo G, Scioscia G, Soccio P, Tondo P, De Pace CC, Sabato R, Foschino Barbaro MP and Lacedonia D: Effect of hypoxia-induced micro-RNAs expression on oncogenesis. Int J Mol Sci. 23:62942022. View Article : Google Scholar : PubMed/NCBI
52	Wang X, Lan Z, He J, Lai Q, Yao X, Li Q, Liu Y, Lai H, Gu C, Yan Q, et al: LncRNA SNHG6 promotes chemoresistance through ULK1-induced autophagy by sponging miR-26a-5p in colorectal cancer cells. Cancer Cell Int. 19:2342019. View Article : Google Scholar : PubMed/NCBI
53	Liu J, Ke F, Chen T, Zhou Q, Weng L, Tan J, Shen W, Li L, Zhou J, Xu C, et al: MicroRNAs that regulate PTEN as potential biomarkers in colorectal cancer: A systematic review. J Cancer Res Clin Oncol. 146:809–820. 2020. View Article : Google Scholar : PubMed/NCBI
54	Xu M, Chen X, Lin K, Zeng K, Liu X, Xu X, Pan B, Xu T, Sun L, He B, et al: lncRNA SNHG6 regulates EZH2 expression by sponging miR-26a/b and miR-214 in colorectal cancer. J Hematol Oncol. 12:32019. View Article : Google Scholar : PubMed/NCBI
55	Gao J, Li L, Wu M, Liu M and Xie X, Guo J, Tang H and Xie X: MiR-26a inhibits proliferation and migration of breast cancer through repression of MCL-1. PLoS One. 8:e651382013. View Article : Google Scholar : PubMed/NCBI
56	Yang Y, Zhang P, Zhao Y, Yang J, Jiang G and Fan J: Decreased MicroRNA-26a expression causes cisplatin resistance in human non-small cell lung cancer. Cancer Biol Ther. 17:515–525. 2016. View Article : Google Scholar : PubMed/NCBI
57	Rokavec M, Öner MG, Li H, Jackstadt R, Jiang L, Lodygin D, Kaller M, Horst D, Ziegler PK, Schwitalla S, et al: IL-6R/STAT3/miR-34a feedback loop promotes EMT-mediated colorectal cancer invasion and metastasis. J Clin Invest. 124:1853–1867. 2014. View Article : Google Scholar : PubMed/NCBI
58	Werner TV, Hart M, Nickels R, Kim YJ, Menger MD, Bohle RM, Keller A, Ludwig N and Meese E: MiR-34a-3p alters proliferation and apoptosis of meningioma cells in vitro and is directly targeting SMAD4, FRAT1 and BCL2. Aging (Albany NY). 9:932–954. 2017. View Article : Google Scholar : PubMed/NCBI
59	Velaei K, Samadi N, Barazvan B and Soleimani Rad J: Tumor microenvironment-mediated chemoresistance in breast cancer. Breast. 30:92–100. 2016. View Article : Google Scholar : PubMed/NCBI
60	Scholten DJ II, Timmer CM, Peacock JD, Pelle DW, Williams BO and Steensma MR: Down regulation of Wnt signaling mitigates hypoxia-induced chemoresistance in human osteosarcoma cells. PLoS One. 9:e1114312014. View Article : Google Scholar : PubMed/NCBI
61	Muz B, Kusdono HD, Azab F, de la Puente P, Federico C, Fiala M, Vij R, Salama NN and Azab AK: Tariquidar sensitizes multiple myeloma cells to proteasome inhibitors via reduction of hypoxia-induced P-gp-mediated drug resistance. Leuk Lymphoma. 58:2916–2925. 2017. View Article : Google Scholar : PubMed/NCBI
62	Mirnezami AH, Pickard K, Zhang L, Primrose JN and Packham G: MicroRNAs: Key players in carcinogenesis and novel therapeutic targets. Eur J Surg Oncol. 35:339–347. 2009. View Article : Google Scholar : PubMed/NCBI
63	Munk R, Panda AC, Grammatikakis I, Gorospe M and Abdelmohsen K: Senescence-associated MicroRNAs. Int Rev Cell Mol Biol. 334:177–205. 2017. View Article : Google Scholar : PubMed/NCBI
64	Vienberg S, Geiger J, Madsen S and Dalgaard LT: MicroRNAs in metabolism. Acta Physiol (Oxf). 219:346–361. 2017. View Article : Google Scholar : PubMed/NCBI
65	Si W, Shen J, Zheng H and Fan W: The role and mechanisms of action of microRNAs in cancer drug resistance. Clin Epigenetics. 11:252019. View Article : Google Scholar : PubMed/NCBI
66	Tiwari A, Mukherjee B and Dixit M: MicroRNA key to angiogenesis regulation: MiRNA biology and therapy. Curr Cancer Drug Targets. 18:266–277. 2018. View Article : Google Scholar : PubMed/NCBI
67	Oikawa T, Otsuka Y and Sabe H: p53-dependent and -independent epithelial integrity: beyond miRNAs and metabolic fluctuations. Cancers (Basel). 10:1622018. View Article : Google Scholar : PubMed/NCBI
68	Blume CJ, Hotz-Wagenblatt A, Hüllein J, Sellner L, Jethwa A, Stolz T, Slabicki M, Lee K, Sharathchandra A, Benner A, et al: p53-dependent non-coding RNA networks in chronic lymphocytic leukemia. Leukemia. 29:2015–2023. 2015. View Article : Google Scholar : PubMed/NCBI
69	Ueno T, Toyooka S, Fukazawa T, Kubo T, Soh J, Asano H, Muraoka T, Tanaka N, Maki Y, Shien K, et al: Preclinical evaluation of microRNA-34b/c delivery for malignant pleural mesothelioma. Acta Med Okayama. 68:23–26. 2014.PubMed/NCBI
70	Suh SO, Chen Y, Zaman MS, Hirata H, Yamamura S, Shahryari V, Liu J, Tabatabai ZL, Kakar S, Deng G, et al: MicroRNA-145 is regulated by DNA methylation and p53 gene mutation in prostate cancer. Carcinogenesis. 32:772–778. 2011. View Article : Google Scholar : PubMed/NCBI
71	Huang Y, Kesselman D, Kizub D, Guerrero-Preston R and Ratovitski EA: Phospho-ΔNp63α/microRNA feedback regulation in squamous carcinoma cells upon cisplatin exposure. Cell Cycle. 12:684–697. 2013. View Article : Google Scholar : PubMed/NCBI
72	Bisio A, De Sanctis V, Del Vescovo V, Denti MA, Jegga AG, Inga A and Ciribilli Y: Identification of new p53 target microRNAs by bioinformatics and functional analysis. BMC Cancer. 13:5522013. View Article : Google Scholar : PubMed/NCBI
73	Suzuki HI, Yamagata K, Sugimoto K, Iwamoto T, Kato S and Miyazono K: Modulation of microRNA processing by p53. Nature. 460:529–533. 2009. View Article : Google Scholar : PubMed/NCBI
74	Kulshreshtha R, Ferracin M, Wojcik SE, Garzon R, Alder H, Agosto-Perez FJ, Davuluri R, Liu CG, Croce CM, Negrini M, et al: A microRNA signature of hypoxia. Mol Cell Biol. 27:1859–1867. 2007. View Article : Google Scholar : PubMed/NCBI
75	Liao JM, Cao B, Zhou X and Lu H: New insights into p53 functions through its target microRNAs. J Mol Cell Biol. 6:206–213. 2014. View Article : Google Scholar : PubMed/NCBI
76	Rokavec M, Li H, Jiang L and Hermeking H: The p53/microRNA connection in gastrointestinal cancer. Clin Exp Gastroenterol. 7:395–413. 2014.PubMed/NCBI
77	Du R, Sun W, Xia L, Zhao A, Yu Y, Zhao L, Wang H, Huang C and Sun S: Hypoxia-induced down-regulation of microRNA-34a promotes EMT by targeting the Notch signaling pathway in tubular epithelial cells. PLoS One. 7:e307712012. View Article : Google Scholar : PubMed/NCBI
78	Zhou B, Wei E, Shi H, Huang J, Gao L, Zhang T, Wei Y and Ge B: MiR-26a inhibits cell proliferation and induces apoptosis in human bladder cancer through regulating EZH2 bioactivity. Int J Clin Exp Pathol. 10:11234–11241. 2017.PubMed/NCBI
79	Li P, Zhang X, Wang H, Wang L, Liu T, Du L, Yang Y and Wang C: MALAT1 is associated with poor response to oxaliplatin-based chemotherapy in colorectal cancer patients and promotes chemoresistance through EZH2. Mol Cancer Ther. 16:739–751. 2017. View Article : Google Scholar : PubMed/NCBI
80	Sun C, Wang FJ, Zhang HG, Xu XZ, Jia RC, Yao L and Qiao PF: miR-34a mediates oxaliplatin resistance of colorectal cancer cells by inhibiting macroautophagy via transforming growth factor-β/Smad4 pathway. World J Gastroenterol. 23:1816–1827. 2017. View Article : Google Scholar : PubMed/NCBI
81	Shi X, Kaller M, Rokavec M, Kirchner T, Horst D and Hermeking H: Characterization of a p53/miR-34a/CSF1R/STAT3 feedback loop in colorectal cancer. Cell Mol Gastroenterol Hepatol. 10:391–418. 2020. View Article : Google Scholar : PubMed/NCBI
82	Wu T, Wang Z, Liu Y, Mei Z, Wang G, Liang Z, Cui A, Hu X, Cui L, Yang Y and Liu CY: Interleukin 22 protects colorectal cancer cells from chemotherapy by activating the STAT3 pathway and inducing autocrine expression of interleukin 8. Clin Immunol. 154:116–126. 2014. View Article : Google Scholar : PubMed/NCBI
83	Jahid S, Sun J, Edwards RA, Dizon D, Panarelli NC, Milsom JW, Sikandar SS, Gümüs ZH and Lipkin SM: miR-23a promotes the transition from indolent to invasive colorectal cancer. Cancer Discov. 2:540–553. 2012. View Article : Google Scholar : PubMed/NCBI
84	Huang S, He X, Ding J, Liang L, Zhao Y, Zhang Z, Yao X, Pan Z, Zhang P, Li J, et al: Upregulation of miR-23a approximately 27a approximately 24 decreases transforming growth factor-beta-induced tumor-suppressive activities in human hepatocellular carcinoma cells. Int J Cancer. 123:972–978. 2008. View Article : Google Scholar : PubMed/NCBI
85	Li X, Li X, Liao D, Wang X, Wu Z, Nie J, Bai M, Fu X, Mei Q and Han W: Elevated microRNA-23a expression enhances the chemoresistance of colorectal cancer cells with microsatellite instability to 5-fluorouracil by directly targeting ABCF1. Curr Protein Pept Sci. 16:301–309. 2015. View Article : Google Scholar : PubMed/NCBI
86	Peng F, Zhang H, Du Y and Tan P: miR-23a promotes cisplatin chemoresistance and protects against cisplatin-induced apoptosis in tongue squamous cell carcinoma cells through twist. Oncol Rep. 33:942–950. 2015. View Article : Google Scholar : PubMed/NCBI
87	Xu F, Li Q, Wang Z and Cao X: Sinomenine inhibits proliferation, migration, invasion and promotes apoptosis of prostate cancer cells by regulation of miR-23a. Biomed Pharmacother. 112:1085922019. View Article : Google Scholar : PubMed/NCBI
88	Zhang YS, Wang MY, Zhang WL and Tang CH: Proliferation, migration and apoptosis of acute myeloid leukemia cells regulated by mir-23a-3p targeting SMC1A and the mechanism. Zhonghua Zhong Liu Za Zhi. 41:753–759. 2019.(In Chinese). PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

P53‑microRNA interactions regulate the response of colorectal tumor cells to oxaliplatin under normoxic and hypoxic conditions

This article is mentioned in:

Abstract

Figure 1

Figure 2

Figure 3

Figure 4

Figure 5

Figure 6

Figure 7

Figure 8

Figure 9

Related Articles